ArticleNature communications2025
Oropouche virus infects human trophoblasts and placenta explants.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Emerging threat of Oropouche virus: Clinical features, experimental models, and virulence.Virulence · 2026Review
- Oropouche virus infection: clinical spectrum, geographic expansion, and emerging maternal-fetal implications.Infection · 2026Review
- Comparative analysis of host responses to Oropouche viruses in placental cell infection models.PLoS neglected tropical diseases · 2026Article
- Oropouche virus causes severe congenital disease in embryonic mice.Nature communications · 2026Article
- Article
- Molecular and Serological Evidence of Oropouche Virus Circulation in Asymptomatic Blood Donors During the 2023-2024 Outbreak in Manaus, Brazil.The Journal of infectious diseases · 2026Article
- Microcephaly-like phenotype triggered by novel reassortant and prototypic Oropouche virus strains in brain organoids.EBioMedicine · 2026Article
- Placenta models for HIV-1-ART-nicotine comorbidity research: advances and remaining challenges.Cell death discovery · 2026Review
- Oropouche virus: transmission, epidemiology, genetic diversity, and public health implications.EClinicalMedicine · 2026Review
- Comprehensive analysis of epidemiological and clinical features of Oropouche virus infection (1975 to 2025): a systematic review.New microbes and new infections · 2026Review
- Susceptibility of Livestock, Wildlife, and Domestic Host Species Cells to the 2022-2025 Reassortant Oropouche Virus.Pathogens (Basel, Switzerland) · 2026Article
- Oropouche virus infects human neural progenitor cells and alters the growth of brain organoids.iScience · 2026Article
- Recent insights into the immunobiology of congenital cytomegalovirus infection.Current opinion in physiology · 2026Article
- Type I interferon controls vertical transmission and fetoplacental infection of Oropouche virus.iScience · 2026Article
- Interleukin-27 is antiviral against Zika virus at the maternal-fetal interface.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Clinical and epidemiologic evidence from the 2023-24 outbreak of Oropouche virus (OROV) has demonstrated increased severity in clinical disease and adverse pregnancy outcomes including miscarriage, stillbirth, and neonatal demise. Serological evidence suggests vertical transmission of OROV may be responsible. OROV has not been studied in the context of pregnancy and has an unknown ability to infect the relevant tissues of the maternal-fetal interface; therefore, the mechanisms of vertical transmission are unknown. We use human cytotrophoblast and syncytiotrophoblast stem cell cultures, polarized trophoblast stem cell organoids, and placenta explants to demonstrate that OROV (BeAn19991) infects and replicates in human tissues of the maternal-fetal interface including cytotrophoblasts and the microbial-resistant cell, syncytiotrophoblast. Viral replication is robust within the first 24 hour post infection and infection may be dependent on gestational age. These data indicate tissues at the maternal-fetal interface are susceptible to OROV infection and may facilitate vertical transmission, leading to adverse pregnancy outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.